Health Canada has instituted numerous measures to help address and combat COVID-19, from facilitating access to COVID-19 products to protecting the public from false or misleading advertisements claiming to prevent, treat or diagnose COVID-19 (see our previous bulletins on these issues in the “Health Canada's response to COVID-19” section).
Given the extensive measures instituted, Health Canada has also published documents summarizing its various measures. Health Canada’s regulatory response to COVID-19: Access to health products is one particularly helpful document.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
New guidance documents and regulatory amendments regarding therapeutic product shortages
As we have previously reported, in response to the COVID-19 pandemic, the Minister of Health had made interim orders pursuant to the Food and Drugs Act to address the significant risk to health posed ...Read More -
Competition Bureau resolves misleading performance claims case
On April 27, 2022, the Competition Bureau announced that it has reached a settlement agreement with NuvoCare Health Sciences Inc and its founder (collectively “NuvoCare”), who were found to have made ...Read More -
Supreme Court of Canada denies leave to appeal refusal of NHP licence for BOLUOKE
On May 12, 2022, the Supreme Court of Canada dismissed an application by Canada RNA Biochemical (C-RNA) for leave to appeal (Docket No. 39994) a decision of the Federal Court of Appeal relating to the...Read More